GGrantIndex
← Leaderboards

Thomas C Merigan

Stanford University

Google Scholar ↗PubMed ↗ORCID ↗
$8,107,440
Attributed
$8,107,440
Total exposure
34
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $266.1K · FY2005–07
$500K$375K$250K$125K$0
'05
'06
'07

Funding mix

By agency

NIH$8,107,440 · 34

By mechanism

U01$6,930,521 · 1
M01$1,176,919 · 33

Top collaborators

No co-investigators on record.

Most similar at Stanford University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHuman SubjectAids TherapyHiv InfectionsHuman Therapy EvaluationAntiaids AgentHuman Immunodeficiency Virus 1Patient Oriented ResearchPharmacokineticsCombination ChemotherapyProtease InhibitorLongitudinal Human StudyDrug Screening /EvaluationClinical Trial Phase IEfavirenzVirus RnaBody CompositionOpportunistic InfectionsTherapy ComplianceDrug InteractionsRitonavirImmunotherapyAidsCytomegalovirus

Grant awards (58)

MANAGEMENT OF HEPATITIS C VIRUS (HCV) AND HIV-1 CO-INFECTED SUBJECTS$47,400
M01 · FY2007 · RR · contact PI
DETERMINE TIME TO DEVELOPMENT OF AIDS DEFINING COMPLICATIONS & INFECTIONS$20,859
M01 · FY2007 · RR · contact PI
A5132 TRIAL TO EVALUATE INTERLEUKIN-2 (IL-2) POTENT ANTIRETROVIRAL THERAPY$3,798
M01 · FY2007 · RR · contact PI
ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS AND HIV-1 CO-INFECTED SUBJECTS$63,232
M01 · FY2006 · RR · contact PI
STUDY ON ABILITY TO ENHANCE HIV-SPECIFIC IMMUNE RESPONSES$17,748
M01 · FY2006 · RR · contact PI
DETERMINE TIME TO DEVELOPMENT OF AIDS DEFINING COMPLICATIONS & INFECTIONS$13,312
M01 · FY2006 · RR · contact PI
HIV SUBJECTS WITH DECREASED BONE MINERAL DENSITY RECEIVING CALCIUM AND VITAMIN D$8,876
M01 · FY2006 · RR · contact PI
GENE CONSTRUCT IN THE TREATMENT OF PATIENTS WITH HIV-1 INFECTION$90,772
M01 · FY2005 · RR
ACTG 5001 ADULT AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED$66,512
M01 · FY2005 · RR
TRIAL OF VALGANCICLOVIR ACTG 5030 AIDS STUDY$21,128
M01 · FY2005 · RR
STUDY ON ABILITY TO ENHANCE HIV-SPECIFIC IMMUNE RESPONSES$21,128
M01 · FY2005 · RR
HIV SUBJECTS WITH DECREASED BONE MINERAL DENSITY RECEIVING CALCIUM AND VITAMIN D$14,867
M01 · FY2005 · RR
DETERMINE TIME TO DEVELOPMENT OF AIDS DEFINING COMPLICATIONS &INFECTIONS$10,956
M01 · FY2005 · RR
PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV INFECTION$9,390
M01 · FY2005 · RR
ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS AND HIV-1 CO-INFECTED SUBJECTS$9,390
M01 · FY2005 · RR
PULSE THERAPY ON THE CHARACTERISTICS OF TREATMENT INTERRUPTIONS AIDS$7,824
M01 · FY2005 · RR
RIBAVIRIN ON ZIDOVUDINE OR STAVUDINE TRIPHOSPHATE FORMATION A5092S IN AIDS$5,477
M01 · FY2005 · RR
TREATMENT OF ELEVATED NON-HDL CHOLESTEROL AND ELEVATED TRIGLYCERIDES IN HIV$3,913
M01 · FY2005 · RR
VIROLOGIC STUDIES IN COMPARTMENTAL SAMPLES FROM HIV-INFECTED SUBJECTS$3,129
M01 · FY2005 · RR
HIV SUBJECTS WITH FAILURE OF PREVIOUS PROTEASE INHIBITOR-BASED REGIMENS$1,566
M01 · FY2005 · RR
Pharmacokinetic Interaction Study: Amprenavir, Efavirenz$30,296
M01 · FY2004 · RR
ACTG 5001 Adult Aids Clinical Trials Group Longitudinal Linked Randomized$29,169
M01 · FY2004 · RR
A5170 PREDICTORS OF IMMUNOLOGIC AND CLINICAL PROGRESSION IN SUBJECTS WITH CD4+$19,634
M01 · FY2004 · RR
PHARMACOKINETIC EVALUATION OF THE EFFECTS OF RIBAVIRIN$13,463
M01 · FY2004 · RR
Determine Time to Development of AIDS Defining Infection$12,903
M01 · FY2004 · RR
A5102 An Open-Label, Pilot Study Utilizing CD4+ T-Cells$12,340
M01 · FY2004 · RR
Virologic Studies in Compartmental Samples for HIV$10,097
M01 · FY2004 · RR
A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND TRIAL OF VALGANCICLOVIR P...$8,975
M01 · FY2004 · RR
ACTG 5095 Phase III, Randomized, Double-Blind Comparison of Three Protease$8,975
M01 · FY2004 · RR
Combinations of Potent Antiretroviral Therapy$7,292
M01 · FY2004 · RR
A5142 A PHASE III RANDOMIZED, OPEN-LABEL COMPARISON$7,292
M01 · FY2004 · RR
A Randomized, Double-Blind, Placebo-Controlled Study$6,171
M01 · FY2004 · RR
PHASE I/II RANDOM, DOUBLE-BLIND, PLACEBO-CONTROL STUDY$5,609
M01 · FY2004 · RR
A5148 A PILOT STUDY OF THE SAFETY AND EFFICACY OF NIACIN$5,609
M01 · FY2004 · RR
Prolongation of Virologic Success$5,049
M01 · FY2004 · RR
A5132 AN EXPLORATORY, OPEN-LABEL, RANDOMIZED TRIAL$3,926
M01 · FY2004 · RR
A5126 A PHASE II STUDY OF THE PREDICTIVE VALUE$3,366
M01 · FY2004 · RR
A5146 A RANDOMIZED CONTROLLED TRIAL$2,805
M01 · FY2004 · RR
A5163 A PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY$2,805
M01 · FY2004 · RR
A RANDOMIZED PHASE II, DOUBLE-BLIND, CONTROLLED TRIAL$560
M01 · FY2004 · RR
AIDS CLINICAL TRIALS UNIT$1,625,577
U01 · FY2003 · AI
AIDS CLINICAL TRIALS UNIT$58,244
U01 · FY2003 · AI
AIDS CLINICAL TRIALS UNIT$1,693,188
U01 · FY2002 · AI
AIDS CLINICAL TRIALS UNIT$1,921,768
U01 · FY2001 · AI
AMPRENAVIR FOR HIV MULTI DRUG RESISTANCE$134,676
M01 · FY2001 · RR
HIGH PROTEIN SUPPLEMENT IN HIV WITH STABLE WEIGHT LOSS$134,676
M01 · FY2001 · RR
ANTIRETROVIRAL THERAPY FOR HIV W/ NELFINAVIR FAILURE$134,676
M01 · FY2001 · RR
ANTIVIRAL ACTIVITY OF T 1249 IN HIV-1 INFECTION$134,676
M01 · FY2001 · RR
AMPRENAVIR FOR HIV MULTI DRUG RESISTANCE$0
M01 · FY2001 · RR
HIGH PROTEIN SUPPLEMENT IN HIV WITH STABLE WEIGHT LOSS$0
M01 · FY2001 · RR
ANTIRETROVIRAL THERAPY FOR HIV W/ NELFINAVIR FAILURE$0
M01 · FY2001 · RR
ANTIVIRAL ACTIVITY OF T 1249 IN HIV-1 INFECTION$0
M01 · FY2001 · RR
AIDS CLINICAL TRIALS UNIT$1,631,744
U01 · FY2000 · AI
EFFECT OF FOUR DRUG/DOUBLE PROTEASE INHIBITOR THERAPY IN HIV PATIENTS$602
M01 · FY2000 · RR
ANTIRETROVIRAL THERAPY FOR HIV W/ NELFINAVIR FAILURE$0
M01 · FY2000 · RR
ANTIVIRAL ACTIVITY OF T 1249 IN HIV-1 INFECTION$0
M01 · FY2000 · RR
HIGH PROTEIN SUPPLEMENT IN HIV WITH STABLE WEIGHT LOSS$0
M01 · FY2000 · RR
AMPRENAVIR FOR HIV MULTI DRUG RESISTANCE$0
M01 · FY2000 · RR